ECS Botanics Holdings (ASX:ECS) Research & Development: A$0.01 Mil (TTM As of Dec. 2025)


What is ECS Botanics Holdings Research & Development?

ECS Botanics Holdings ASX:ECS -11.11% Research & Development is A$0.01 Mil as of Dec. 2025. The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. ECS Botanics Holdings's Research & Development for the six months ended in Dec. 2025 was A$0.01 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.01 Mil.

ECS Botanics Holdings  (ASX:ECS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

ECS Botanics Holdings Research & Development Related Terms

ECS Botanics Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for ECS Botanics Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ECS Botanics Holdings Research & Development Chart

ECS Botanics Holdings Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.13 0.02 0.01 0.12

ECS Botanics Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 -0.04 0.00 0.00 0.01

ECS Botanics Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of A$0.01 Mil mean?
ECS Botanics Holdings (ASX:ECS) has a Research & Development of A$0.01 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on ECS Botanics Holdings and its competitors.
Is ECS Botanics Holdings' Research & Development too high?
ECS Botanics Holdings' current Research & Development is A$0.01 Mil.
How does ECS Botanics Holdings' Research & Development compare to ZTS?
ECS Botanics Holdings' Research & Development of A$0.01 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on ECS Botanics Holdings and its competitors. ECS Botanics Holdings's current Research & Development is A$0.01 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ECS Botanics Holdings stock overvalued right now?
Based on GuruFocus' analysis, ECS Botanics Holdings (ASX:ECS) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 80% below its estimated fair value. The current Research & Development is A$0.01 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For ECS Botanics Holdings (ASX:ECS), the current Research & Development is A$0.01 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ECS Botanics Holdings Business Description

Address 899 River Road, Murrabit West, Murrabit, VIC, AUS, 3579
ECS Botanics Holdings Ltd is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. The company utilizes progressive cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licensed by the Therapeutic Drug Administration to manufacture PIC/S GMP certified products, the company provides quality, affordable medicinal cannabis, supplying both local and overseas markets.